NCT01143974已完成4 期
Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- PFS (progression free survival)
研究概览
简要总结
For patients resistant to enthrycycline and taxanes, there is no standard regimen. Pemetrexed alone had certain efficacy in treatment of advance breast cancer. Platin was also a effective drug for advanced breast cancer. The combination of these two drug may have a synergy with each other in treatment of advanced breast cancer.
详细描述
combination of pemetrexed and cisplatin to treat advanced breast cancer. Previous regimen no more than 3 which including enthrycycline and taxanes(paclitaxel and/or docetaxel)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •18-70 years old
- •Resistant to enthracycle and taxanes
- •Has measurable disease
排除标准
- •Has more than 3 previous chemotherapy regimens
研究组 & 干预措施
PC Regimen
Experimental
干预措施: pemetrexed plus cisplatin (Drug)
结局指标
主要结局
PFS (progression free survival)
时间窗: 2 Years
次要结局
- Safety(2 years)
- Response Rate(2 years)
研究者
Peng Yuan
Associate chief physician
Chinese Academy of Medical Sciences
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Efficacy and safety of Adjuvant Pemetrexed plus cisplatin for post-operative adenocarcinomaKCT0002816Chonnam National University Hospital Hwasun Hospital106
进行中（未招募）
不适用
A Phase II Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055MedDRA version: 9.1Level: LLTClassification code 10025054EUCTR2008-004330-24-ITEli Lilly and Company125
终止
2 期
Pemetrexed and Cisplatin as Treatment in Small Cell Lung CancerSmall Cell Lung CancerNCT00475657Eli Lilly and Company5
进行中（未招募）
不适用
Phase I/II study with cisplatin and pemetrexed +/- sorafenib in malignant pleural mesothelioma (SoMe study) - SoMe Studymalignant pleural mesothelioma (MPM)MedDRA version: 9.1Level: LLTClassification code 10059518Term: Pleural mesothelioma malignantEUCTR2007-005894-77-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
已完成
2 期
Phase II study of Pemetrexed and Cisplatin plus Bevacizumab with Maintenance Pemetrexed as First-Line Therapy for Nonsquamous Non-small-cell Lung Cancer (ALCT001)onsquamous Non-small-cell Lung CancerJPRN-UMIN000010804Kyorin Univercity Hospital25